Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
about
Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humansHomology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluationThe effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats.Inner Hair Cell Loss Disrupts Hearing and Cochlear Function Leading to Sensory Deprivation and Enhanced Central Auditory Gain.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsPramipexole-induced somnolence and episodes of daytime sleep.Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457.Pre-clinical studies of pramipexole: clinical relevance.A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonistA review of pramipexole and its clinical utility in Parkinson's disease.Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre studyPlacebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunctionUpdate on the use of pramipexole in the treatment of Parkinson's disease.Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence.Prolactin and fMRI response to SKF38393 in the baboon.Dopaminergic influences on emotional decision making in euthymic bipolar patientsPharmacokinetic evaluation of pramipexole.The benefits of pramipexole selection in the treatment of Parkinson's disease.Pramipexole extended-release: a review of its use in patients with Parkinson's disease.Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.Syndrome of inappropriate antidiuretic hormone secretion associated with pramipexole in a patient with Parkinson's disease.Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.Transgenic mice to study the role of dopamine receptors in cardiovascular function.Pramipexole extended release: a novel treatment option in Parkinson's disease.Syndrome of inappropriate antidiuretic hormone secretion associated with pramipexole in a patient with Parkinson's disease.Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms.Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants.Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.The Acute Effects of a Dopamine D3 Receptor Preferring Agonist on Motivation for Cigarettes in Dependent and Occasional Cigarette Smokers.Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.In silico profiling of systemic effects of drugs to predict unexpected interactions.Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report.Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release.
P2860
Q28265851-8A52EB5C-90A8-4E98-B560-7E4BC511E9FDQ28483632-908ACA1E-A496-4485-A002-165A3A964714Q30305696-E890D48A-5AAB-4A45-AE23-2421AEF31F44Q30364449-311195BD-0293-4919-8174-6A8272AF9F0BQ30486707-D71D61E2-3DE9-4BC7-B6AD-45742CA7A3BBQ31422765-AAA4ABEB-07EF-4C2A-AC5B-DAF4F999A80BQ33847160-16FCDA85-B70D-4468-9C30-F8FDAE91FD42Q34071719-CFAEACC0-1464-4EEC-9163-468A6CC9FCF2Q34431032-10D7B44F-CA65-40B2-9CAA-53EC009E3B73Q34519277-859D9D59-1FAF-4FA0-9FED-57236A25F881Q34982537-3A671DC5-4196-474A-BECC-7BD9381DE07AQ35000860-32CA3101-DBA7-4F80-A757-39D387BCC055Q35042094-28887081-54D3-419F-BF41-F781ABE371B8Q35450779-BE837454-F8C6-4575-80FE-4C1846BFF44AQ35468072-E2989208-93CB-4624-AF99-A1D83E439A27Q35688126-1C93BE79-CD82-4C98-9BF2-09D30AFD888CQ36842189-95279280-C7A5-45EB-A0A0-9F5CC5CE84BCQ36878368-5AD46498-0151-4AE1-B499-77A9DF50D7E1Q37279952-C2C43B5D-3641-4865-BB1F-5F62FC9FAC05Q37409558-DABF1273-4D9F-4AD2-B3F3-D8F6CE1EDF4FQ37926588-69BA0A6E-75C4-4FC7-966A-D9C0FA4C7D39Q38231222-859BEF8F-DC58-47D6-8F41-E73C8BD38D06Q38266818-A5B1DF34-4DE6-45C0-96A1-34FE3288FC2CQ38342094-6BCE5527-CE22-473B-92BC-3BD3B47FE504Q38656262-94CDCC5D-A93D-4399-B46F-0893BE019A99Q39783880-C22FA594-8F59-45D7-9558-8B4AC35D8FD2Q40440490-A748F6F5-8D60-4C9F-B03F-94405F719DECQ41348295-C6AF28FC-3DD0-48E5-AEF3-17D0ED5E458AQ41487562-C03B0F93-3B25-403B-9FD0-675D11BC14AFQ42118723-65F62D69-E0DE-45D6-93F0-BBE74D61E97FQ43194163-7C8B7702-6356-451E-A6EC-21F4D5BFB5CEQ45197253-B1859D7A-CD32-4BF4-A2F5-D51CC4EBF4F0Q46205987-766F9E5E-1B98-4C68-93B7-5AABFD5FC38CQ46329263-FB5E51A6-70FF-4AA6-B109-AE09EE3C219FQ46566287-DB20BF32-C30C-417D-9639-396506646045Q47311914-19100E10-2DAC-4F51-BF90-F936E340D8E8Q47704925-889704A5-E470-4D8D-9E9E-CBFF1D426D6CQ47838952-484549A6-3331-424C-9B4D-3EF305446E76Q48073684-B9E21ADE-4071-4024-B759-62B947A6CACDQ48416131-7F0BB828-E178-440A-9B2B-E6E502360AF6
P2860
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Pramipexole binding and activa ...... amine D2, D3 and D4 receptors.
@en
Pramipexole binding and activa ...... amine D2, D3 and D4 receptors.
@nl
type
label
Pramipexole binding and activa ...... amine D2, D3 and D4 receptors.
@en
Pramipexole binding and activa ...... amine D2, D3 and D4 receptors.
@nl
prefLabel
Pramipexole binding and activa ...... amine D2, D3 and D4 receptors.
@en
Pramipexole binding and activa ...... amine D2, D3 and D4 receptors.
@nl
P2093
P1476
Pramipexole binding and activa ...... amine D2, D3 and D4 receptors.
@en
P2093
P356
10.1016/0922-4106(95)90013-6
P407
P577
1995-06-01T00:00:00Z